Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer. [electronic resource]
Producer: 20050518Description: 61-7 p. digitalISSN:- 0036-5521
- Administration, Oral
- Animals
- Biopsy, Needle
- Colorectal Neoplasms -- drug therapy
- Disease Models, Animal
- Drug Administration Schedule
- Immunohistochemistry
- Intestinal Mucosa -- drug effects
- Lactones -- pharmacology
- Male
- Probability
- Random Allocation
- Rats
- Rats, Wistar
- Reference Values
- Sensitivity and Specificity
- Sulfones -- pharmacology
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.